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Abstract 
Background: The increased resistance of the human malaria parasite Plasmodium falciparum to currently employed 
drugs creates an urgent call for novel anti-malarial drugs. Particularly, efforts should be devoted to developing fast-
acting anti-malarial compounds in case clinical resistance increases to the first-line artemisinin-based combination 
therapy. SC83288, an amicarbalide derivative, is a clinical development candidate for the treatment of severe malaria. 
SC83288 is fast-acting and able to clear P. falciparum parasites at low nanomolar concentrations in vitro, as well as in 
a humanized SCID mouse model system in vivo. In this study, the antiplasmodial activity of SC83288 against arte-
misinins was profiled in order to assess its potential to replace, or be combined with, artemisinin derivatives.
Results: Based on growth inhibition and ring survival assays, no cross-resistance was observed between artemisinins 
and SC83288, using parasite lines that were resistant to either one of these drugs. In addition, no synergistic or 
antagonistic interaction was observed between the two drugs. This study further confirmed that SC83288 is a fast 
acting drug in several independent assays. Combinations of SC83288 and artesunate maintained the rapid parasite 
killing activities of both components.
Conclusion: The results obtained in this study are consistent with artemisinins and SC83288 having distinct modes 
of action and different mechanisms of resistance. This study further supports efforts to continue the clinical develop-
ment of SC83288 against severe malaria as an alternative to artemisinins in areas critically affected by artemisinin-
resistance. Considering its fast antiplasmodial activity, SC83288 could be combined with a slow-acting anti-malarial 
drug.
Keywords: Plasmodium falciparum, Anti-malarial drug, Artemisinin, Severe malaria, Drug development, Artemisinin-
based combination therapy, Resistance
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Background
Despite a decline in global malaria mortality during the 
previous decade, the human malaria parasite Plasmo-
dium falciparum continues to infect more than 200 mil-
lion people annually, causing approximately 450,000 
deaths per year [1]. A main factor in the relative suc-
cess in decreasing malaria-related deaths was the intro-
duction of the highly efficient chemotherapeutic agent 
artemisinin (Fig.  1a) and its derivatives (Fig.  1b, c). 
Partnered with other drugs as artemisinin-based com-
bination therapy (ACT), artemisinins have formed the 
backbone of malaria treatment and control since 2006 
[2]. However, P. falciparum strains displaying delayed and 
possibly reduced responsiveness to ACT have emerged 
in western Cambodia [3], and are now spreading across 
all of Southeast Asia [4, 5]. Accordingly, there is a need 
for new anti-malarial drugs with novel chemical struc-
tures that exploit distinct molecular targets to protect 
them from cross-resistance mechanisms. While several 
clinical candidates fulfilling these criteria are currently 
in preclinical and clinical development [6–19], more 
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candidates are needed to build up a solid and reliable 
reserve library of anti-malarial drugs should the first line 
drugs fail. One such clinical development candidates is 
SC83288 (Fig. 1d), which is considered for the treatment 
of severe malaria [20].
SC83288, an amicarbalide derivative, is active against P. 
falciparum blood stages at low nanomolar concentrations 
in vitro, with  IC50 values of 3 nM. SC83288 is able to clear 
a P. falciparum infection in a humanized NOD/SCID 
mouse model system within 48  h following intraperito-
neal injections of 2.5 mg kg−1 once per day over a period 
of 3  days [20]. Furthermore, SC83288 is fast acting and 
it has favourable pharmacological and toxicological fea-
tures [20]. In vitro resistance to SC83288 develops slowly 
and might involve mutational changes in the  Ca2+ trans-
porting PfATP6, the P. falciparum SERCA orthologue. 
However, PfATP6 does not seem to be the molecular tar-
get of SC83288 but rather a component of resistance [20].
PfATP6 is a validated drug target [21] and was once 
considered the prime molecular target of artemisinins 
[22–25] and a contributor to artemisinin resistance [26–
29]. However, recent studies failed to detect a specific 
interaction between PfATP6 and artemisinins [30–35], 
and instead favour a pleiotropic mode of action in that 
many proteins are covalently modified by the alkylating 
property of artemisinins [36]. Moreover, resistance to 
artemisinins has recently been associated with polymor-
phisms in the kelch propeller domain protein 13 (PfK13) 
[37–46], a member of the kelch protein superfamily, 
bearing multiple protein–protein interaction sites and 
involved, among others, in ubiquitin-regulated protein 
degradation and oxidative stress responses [47].
Considering the gold standard status of artemisinin 
and its derivatives in the anti-malarial drug development 
field and taking into account that PfATP6 has repeatedly 
been considered a drug target of, or a contributor to drug 
resistance, including to SC83288, raises the possibility 
that SC83288 and artemisinins exert their antiplasmodial 
activity, or induce resistance, in P. falciparum in a similar 
or synergistic manner. The data presented herein suggest 
that these concerns are unfounded. No cross-resistance 
was observed between dihydroartemisinin and SC83288 
in vitro. Moreover, both drugs showed neither a synergis-
tic nor antagonistic interaction. Consistent with previous 
results, SC83288 was found to be a fast acting compound, 
although SC83288 is not as rapid regarding its in  vitro 
speed of action as are artemisinins [20]. Furthermore, 
combining SC83288 with artesunate did not affect the 
in  vitro speed of action of either drug, allowing for the 
possibility of a combination therapy.
Methods
Chemicals
The chemicals used in this study were obtained from 
the Roth, Merck, Sigma, Serva, Thermo and Appli-
chem. SC83288 was provided by the 4SC AG, München, 
Germany.
Parasite culture
Plasmodium falciparum parasites were maintained in 
continuous in  vitro culture essentially as previously 
described [48]. Briefly, cultures were maintained at a 
haematocrit of 5.0% and at a parasitaemia of not higher 
than 5% (if not stated otherwise) in RPMI 1640 sup-
plemented with 2  mM l-glutamine, 25  mM HEPES, 
100  µM hypoxanthine, 20  µg  ml−1 gentamycin, 5% 
human heat-inactivated AB-positive serum and 5% Albu-
max. Cultures were incubated at 37 °C under controlled 
atmospheric conditions of 5%  O2, 3%  CO2, 92%  N2 and 
96% humidity. Synchronization of cultures at the ring 
stage was performed using a 5% sorbitol solution as pre-
viously described [49].
Plasmodium falciparum growth inhibition assay
Growth inhibition assays were performed according to a 
standardized protocol, based on the detection of parasite 
DNA by fluorescent SYBRGreen staining [50, 51]. Briefly, 
synchronized cultures of P. falciparum ring-stage para-
sites were incubated in the presence of increasing drug 
concentrations, at the following final condition: 100  µl 
SC83288Dihydroartemisinin
(DHA)
ArtesunateArtemisinin
a b c d
Fig. 1 Structures of various antiplasmodial compounds. a artemisinin, b dihydroartemisinin, c artesunate, and d SC83288
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per well, 0.5% parasitaemia, 2% haematocrit, 72 h incu-
bation at 37 °C. After incubation, the plates were frozen 
at − 80  °C overnight. On the day of the measurement, 
plates were thawed for 1  h at room temperature. The 
plates were filled with 100 µl per well of a 1× SYBRGreen 
(ThermoFisher Scientific Inc.) solution in lysis buffer 
 (H20, 20  mM Tris base pH 7.4, 5  mM EDTA, 0.008% 
(w/v) Saponin, 0.08% (w/v) Triton X-100), briefly shaken 
and incubated at room temperature for 1 h. Plates were 
protected from direct light. Fluorescence was measured 
in a fluorescence plate reader (FluoStar Optima, BMG 
Labtech GmbH) (ext/em: 485/520  nm, gain 1380, 10 
flashes/well, top optic). The  IC50 values were calculated 
using a four parameter sigmoidal function (SigmaPlot 13, 
Systat Software Inc.). 6–13 independent biological repli-
cates were performed, each with technical duplicates.
Ring survival assay
The in  vitro ring survival assay (RSA) rate was assessed 
as previously described [52]. Briefly, tightly synchronized 
early ring parasites (0–3 h post invasion) at a parasitae-
mia of 0.5–1% were exposed to various drugs at a con-
centration of 700 nM for 6 h. The drug was subsequently 
washed-out, and the parasites were returned to culture 
for 66  h before being collected. DNA content analysis 
was performed by flow cytometry on SYBRGreen-stained 
parasites to measure the precise parasitaemia, as previ-
ously described [53], using a BD FACS Canto. Briefly, 
the parasites were fixed in PBS 4% paraformaldehyde, 
0.0075% glutaraldehyde for 2 h at room temperature and 
permeabilized in PBS 0.1% Triton-100 for 8  min. The 
samples were subsequently subjected to a light RNase 
treatment (0.3 mg/ml in PBS) for 30 min at 37 °C. DNA 
was stained with SYBRGreen (1:2000 dilution in PBS) 
for 20 min in the dark. Parasites were then transferred to 
tubes adapted for flow cytometry. The fluorescence sig-
nal was collected in the green channel (FITC-H) of the 
FACS Canto. A minimum of 2000 infected red blood cells 
were counted per measurement and plotted in the form 
of dot-plots, using the software FlowingSoftware2.5.1. 
Parasites survival rates [RSA score (%)] were expressed as 
a percentage, by comparing the parasitaemia between the 
drug-treated and the untreated control as followed: 
3–6 independent biological replicates were performed, 
each with technical duplicates.
Drug interaction study
The interaction profile was assessed using the P. falcipa-
rum strain Dd2 and the fixed-ratio isobologram method 
[54]. This approach is based on determining the  IC50 val-
ues of two individual drugs alone and in combination at 
RSA score (%) = Pdrug−treated(%)/
(
PPBS−treated(%)
)
× 100.
different concentration ratios. In principle, the shift of a 
drug’s  IC50 value, assessed in combination compared to 
the one determined for this drug alone, is indicative of 
the nature of the interaction between the two drugs [54]. 
Briefly, a synchronous culture of ring-stage P. falciparum 
blood-stage parasites was incubated for 72 h in the pres-
ence of increasing drug concentrations in a 96-well black 
microtiter plate. The final conditions of the tests were 
100  µl per well, 0.5% parasitaemia, 2% final haemato-
crit and 72 h incubation time at 37 °C. On the day of the 
assay, a synchronized ring-stage culture, was established 
at 0.5% parasitaemia and 4% haematocrit. A solution of 
uninfected erythrocytes at 4% haematocrit was used as 
a negative control. Drugs were applied alone (A or B) 
and in combination at fixed concentration ratios (A:B) 
and analysed in threefold serial dilutions. Drug mixtures 
were prepared from 2x working solutions of each drug 
in the following fixed concentration ratios (v/v): ratio 
A:B = 4:1, 3:2, 2.5:2.5, 2:3, 1:4, directly in the 96-well 
plate.  IC50 values of drugs A and B alone were deter-
mined on the same plate to ensure accurate calculation 
of drug interactions. After 72 h of incubation, plates were 
wrapped in aluminum foil and frozen at − 80  °C over-
night. Parasite growth was assessed using SYBRGreen 
as described above. Graphical analysis was performed 
on isobolograms, obtained by plotting pairs of fractional 
 IC50  (FIC50) values of drug A and drug B for each com-
bination. The in vitro interactions were evaluated based 
on graphical and arithmetical analysis. It is commonly 
accepted that a mean sum of fractional 50% inhibitory 
concentrations (mean ∑FIC50) lower than 0.5 corre-
sponds to a synergistic interaction, and higher than 1.5 to 
an antagonistic interaction [55]. A mean ∑FIC50 between 
these two cut-off values represents an indifferent interac-
tion between the two investigated drugs. 7 independent 
biological replicates were performed, each with technical 
duplicates.
In vitro speed of action
Two independent methods were used to determine the 
in  vitro speed of action of drugs. The relative speed of 
action was obtained following the approach previously 
described by Le Manach et al. [56]. Briefly, the growth of 
an asynchronous parasite blood culture in the presence 
of anti-malarial compounds was assessed using SYBR-
Green staining and expressed as  IC50 values, as described 
above. For each compound, three exposure times were 
employed 72 (standard assay time), 48 and 24  h. The 
 IC50 ratios, normalized to the 72 h exposure were subse-
quently used to classify the compound as fast- or slow-
acting. The absolute speed of action was obtained using 
the method described by Linnares et  al. [57]. Briefly an 
asynchronous culture of P. falciparum Dd2 blood-stage 
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parasites, at 0.5% parasitaemia and 4% haematocrit was 
treated with a concentration corresponding to 10 × IC50 
for a duration of 8, 14, 24, 48 or 72 h, in a final volume of 
100  µl per well. Drugs were refreshed every 24  h. After 
incubation, the parasites were washed-out in drug free 
medium and resuspended in 100  µl of medium. 70  µl 
were then transferred into a fresh plate, containing 130 µl 
of CFDA-stained uninfected erythrocytes at 2% haema-
tocrit, resulting in a 1/3 dilution. After 48 h of subsequent 
incubation at 37  °C, the parasites were washed in PBS, 
and the DNA was stained using Draq5 (1:500 dilution in 
PBS) for 20 min at room temperature. The samples were 
washed once with PBS and fixed in PBS 0.05% glutaral-
dehyde for 1  h at room temperature. The fixed samples 
were kept in PBS at 4  °C until flow cytometry analysis, 
using a BD FACS Canto. Collecting fluorescence signals 
in the FITC and the PerCP-Cy5 channel allowed the pro-
portion of the double stained infected erythrocytes to be 
determined, which corresponds to the new infections. 
Results were displayed in the form of dot-plots, using the 
software FlowingSoftware2.5.1. The total infections were 
calculated as followed: 
The parasite viability was then expressed as a percentage 
of the untreated parasites. 4 independent biological repli-
cates were performed, each with technical duplicates.
Results
SC83288 shows no cross‑resistance with artemisinins
The matter of cross-resistance between SC83288 and 
artemisinins was initially addressed, using two distinct 
approaches. On the one hand, standard growth inhibition 
assays over 72 h of drug exposure were performed, and 
on the other hand, the susceptibility of early ring stages 
in a ring survival assay (RSA) was evaluated. The RSA 
takes into account the antiplasmodial activity of arte-
misinin and its derivatives against the early blood stages 
[36, 52]. Four different strains of P. falciparum were used 
in these assays: the artemisinin and SC83288 sensitive P. 
falciparum strains NF54 and Dd2, the genetically engi-
neered artemisinin-resistant NF54 mutant line bearing a 
mutation in the kelch 13 gene (PfK13 C580Y), an estab-
lished marker of artemisinin resistance [52], and a Dd2 
derived SC83288 resistant line [20]. The two drug resist-
ant clones were termed  NF54ART  and  Dd2SC.
In the growth inhibition assay, the wild-type NF54 line 
and the  NF54ART  mutant displayed no significant differ-
ence in their dihydroartemisinin responsiveness, with 
 IC50 value of 0.7 ± 0.1 and 0.5 ± 0.1 nM, respectively (Stu-
dent’s t test, p = 0.9) (Table  1 and Fig.  2a). Both strains 
had also comparable susceptibilities to SC83288, with 
 IC50 values of 5.1 ± 0.7 and 4.9 ± 0.8  nM, respectively 
Total infections = 3/2 ∗ RBCCFDA/Draq5.
(Student’s t test, p = 0.2) (Table  1 and Fig.  2b). In com-
parison,  Dd2SC and the parental Dd2 strain revealed 
comparable  IC50 values to dihydroartemisinin (0.5 ± 0.1 
and 0.7 ± 0.1  nM, respectively, Student’s t test, p = 0.8) 
(Table 1 and Fig. 2c) but different responses to SC83288 
(1.0 ± 0.2  µM and 3.1 ± 0.2  nM, respectively, Student’s t 
test, p < 0.001) (Table 1 and Fig. 2d).
Artemisinins have been shown to exert part of their anti-
plasmodial activity against very early ring-stages parasites, 
just after erythrocyte invasion [58, 59]. As expected [52], 
the  NF54ART  line showed a significant difference in its RSA 
score to dihydroartemisinin (DHA) compared to the wild-
type NF54 strain (RSA score of 11.5 ± 1.5 and 24.1 ± 1.9%, 
respectively, Student’s t test, p < 0.001). In comparison, 
Dd2 and  Dd2SC had low and comparable RSA scores of 
9.9 ± 2.7 and 7.7 ± 0.3%, respectively (One-Way ANOVA 
Holm-Sidak test, p = 0.2), indicative of artemisinin sus-
ceptibility (Fig. 3a). Importantly, none of the parasites lines 
showed a ring-stage susceptibility to SC83288 (RSA score 
of 111.0 ± 3.0, 95.7 ± 2.7, 91.4 ± 5.1 and 90.1 ± 3.3%, for 
Dd2,  Dd2SC, NF54, and  NF54ART , respectively; One-Way 
ANOVA Holm-Sidak test, p = 0.8) (Fig.  3b), confirming 
the lack of activity of SC83288 against early ring-stages 
[20]. Taken together, the data from these two independent 
assays strongly suggest against any kind of cross-resistance 
effects between artemisinins and SC83288 in vitro.
SC83288 and artemisinin do not interact
Subsequently, the question was addressed of whether 
artemisinin and SC83288 have an effect on one another 
when combined in a growth inhibition assay. To this end, 
the interaction profile between artemisinin and SC83288 
using a fixed-ratio isobologram method [54] was inves-
tigated. A synchronous culture of Dd2 at the ring stage 
for 72 h was incubated in the presence of increasing drug 
concentrations, whereby artemisinin and SC83288 were 
applied alone and in combination at fixed concentration 
ratios. The arithmetical analysis revealed a mean sum of 
fractional 50% inhibitory concentrations (mean ∑FIC50) 
of 0.97 ± 0.06, suggestive of an indifferent interaction. 
Table 1 Susceptibility of  NF54,  NF54ART , Dd2, and   Dd2SC 
to SC83288 and artemisinin
IC50 inhibitory concentration of 50% of the maximal effect. Mean ± SEM of 6–13 
independent biological replicates
*p < 0.001 as compared with the parental strain
Strain IC50 (nM)
SC83288 Dihydroartemisinin
NF54 5.1 ± 0.7 0.7 ± 0.1
NF54ART 4.9 ± 0.8 0.5 ± 0.1
Dd2 3.1 ± 0.2 0.7 ± 0.1
Dd2SC 1000 ± 200* 0.5 ± 0.5
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The graphical analysis on the isobologram, obtained by 
plotting the pairs of fractional  IC50  (FIC50) values of arte-
misinin and SC83288 for each combination, agreed with 
the arithmetical observation, following almost perfectly 
the diagonal trend line (fit to a linear polynomial curve 
with a  R2 = 0.972) (Fig. 4), thereby corroborating the con-
clusion that both drugs do not interact.
Combining SC83288 and artesunate does not affect 
the in vitro speed of action
First, the in  vitro killing speed of SC83288 was deter-
mined according to the method developed by Le 
Manach et  al. [56], which classifies drugs as slow- or 
fast-acting based on a relative in vitro speed of action. 
To this end, growth inhibition assays were performed, 
using asynchronous cultures of Dd2, and assessed para-
site growth after drug exposure of 24, 48 and 72 h. The 
 IC50 ratios were subsequently normalized to the stand-
ard 72  h incubation assay. For comparative reasons, 
artemisinin and atovaquone were analysed in parallel. 
The  IC50 ratios of SC82388 were independent of the 
exposure time (1.28 ± 0.08, 1.24 ± 0.05 and 1.00 ± 0.06 
for 24, 48 and 72 h of drug exposure, respectively; One-
way ANOVA Holm-Sidak test, p = 0.3), indicating a 
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Fig. 2 Susceptibility of different P. falciparum strains to SC83288 and dihydroartemisinin. a and b Growth inhibition of NF54 and the artemisinin 
resistant derivative  NF54ART  carrying the PfK13 C580Y mutation by artemisinin (a) and SC83288 (b) in a standard cell proliferation assay with 
an exposure time of 72 h. c and d Growth inhibition of Dd2 and the SC83288 resistant derivative  Dd2SC by artemisinin (c) and SC83288 (d). 
Mean ± SEM of 6–13 independent determinations
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fast mode of action. Similarly, the exposure time did 
not affect the  IC50 ratios of artemisinin (0.97 ± 0.07, 
0.88 ± 0.01 and 1.00 ± 0.01 for 24, 48 and 72 h of treat-
ment, respectively; One-way ANOVA Holm-Sidak test, 
p = 0.2). In comparison, the  IC50 ratios of atovaquone 
were significantly different (3.4 ± 0.1, 1.35 ± 0.04 and 
1.00 ± 0.04, for 24, 48 and 72  h of treatment, respec-
tively; One-way ANOVA Holm-Sidak test, p < 0.001) 
(Fig. 5), consistent with atovaquone being a slow acting 
anti-malarial [56, 57, 60].
In order to identify possible detrimental interactions 
between the drugs in the prospect of a potential com-
bination therapy, a second approach was employed 
to evaluate the absolute speed of action of SC83288, 
alone as well as in combination with artesunate or 
atovaquone, based on the method of Linares et al. [57]. 
To this end, asynchronous cultures of Dd2 were treated 
with 10x  IC50 concentrations of SC82388, artesunate 
or atovaquone, alone or in combination, for a duration 
of 8, 14, 24, 48 or 72  h. After washing-out the drugs, 
the parasites were cultured with uninfected erythro-
cytes stained with a live cells marker, the esterase sub-
strate carboxyfluorescein diacetate (cFDA). After 48  h 
of subsequent incubation, the DNA of the parasite was 
stained with Draq5 and the amount of cFDA and Draq5 
stained cells was determined by flow cytometry. The 
results of this assay classified SC83288 as a fast-acting 
anti-malarial compound, with a 90% parasite clearance 
time  (PCT90%) of 17 ± 3 h. In comparison, the measured 
 PCT90% of artesunate and atovaquone were 11 ± 1 h and 
> 80 h, respectively (Fig. 6). Combining artesunate and 
SC83288 did not lead to a significant difference in the 
 PCT90% compared with artesunate alone (9.0 ± 0.5  h, 
Student’s t test, p = 0.1) (Fig.  6). Similarly, combining 
SC83288 with atovaquone did not significantly alter 
the  PCT90% of SC83288 alone (17 ± 6 h Student’s t test, 
p = 0.4) (Fig. 6).
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Fig. 4 Indifferent interaction between artemisinin and SC83288. The 
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and SC83288 in the P. falciparum strain Dd2 were displayed in an 
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Discussion
Understanding the mode of action and the mechanism of 
resistance of a therapeutic agent is not mandatory for a 
compound to be released on the market. However, infor-
mation regarding these processes may help to predict and 
control interactions of the compound with the environ-
ment and with other drugs deployed in the field. To this 
purpose, the antiplasmodial action of SC83288 was pro-
filed against artemisinin and artemisinin derivatives in P. 
falciparum.
The parasite reduction ratio after a single dose, i.e. 
the speed of action of the molecule, is a quality feature 
of an anti-malarial drug as recently emphasized by the 
Medicine for Malaria Venture (MMV) [61]. Particularly, 
drugs against severe malaria are expected to rapidly clear 
sequestered parasites from the patient´s microvascula-
ture, which can make the difference between survival 
and death. Moreover, fast-acting anti-malarial drugs are 
favoured for their ability to reduce the risks of resistant 
parasites arising within the patient. To this day, the arte-
misinin derivatives remain the gold standards of a rap-
idly clearing anti-malarial, reducing the parasite burden 
within hours [2]. SC83288 has previously been charac-
terized as a fast-acting anti-malarial compound in  vitro 
[20] using a recrudescence assay [60]. Under these con-
ditions, the SC83288 speed of action profile was closer 
to the fast-acting artemisinin than to the slow-acting 
atovaquone, although the SC83228 showed a slightly 
longer clearance time and a lower parasite reduction 
ratio compared to artemisinin [20]. On a direct clear-
ance-time measurement using trophozoites, SC83288, 
however, revealed a higher activity than artemisinin [20], 
consistent with the potent antiplasmodial activity of 
SC83288 on trophozoites [20]. In this study, the killing 
speed of SC83288 was verified, using two other methods: 
a relative speed assay [56], and a re-invasion assay [57]. 
The results of these assays were consistent with previ-
ous observations, marking SC83288 as a fast-acting anti-
malarial compound (Figs. 5 and 6), with an in vitro killing 
speed profile closer to artesunate than to atovaquone 
(Fig. 6). Further, combining SC83288 with artesunate did 
not significantly impair the speed of action (Fig. 6). The 
speed of action is, however, not the only crucial aspect 
that needs to be taken into account when developing an 
anti-malarial compound. As for any xenobiotic molecule, 
the beneficial versus adverse effects must be carefully 
weighed, and parameters such as safety, pharmacoki-
netics and drug–drug interactions need to be consid-
ered. In this regard, preliminary results on the safety and 
toxicology of SC83288 in mice and dogs are promising, 
although a full assessment would await clinical trials in 
humans. This study further revealed no obvious in vitro 
interactions between artemisinin and SC83288 in the P. 
falciparum strain Dd2 (Fig.  4). Both the graphical and 
arithmetical analysis of our isobologram method sup-
ported this observation, with the isobologram following 
a linear trend, and a mean sum of fractional 50% inhibi-
tory concentration falling within the range of an indif-
ferent interaction [55]. An isobologram may overlook 
possible similar modes of action, particularly if the two 
tested compounds are both either competitive inhibitors 
or mutually exclusive non-competitive inhibitors [55]. 
Competition of both compounds for the same binding 
site, independently of an interference with the binding 
site of the endogenous substrate, would not be noticed in 
an isobologram [55]. However, the chemical and struc-
tural differences between SC83288 and the artemisinins 
(Fig. 1) strongly argue against this possibility.
Resistance is another key aspect of the MMV’s drug 
candidate profile. Indeed, resistance to most marketed 
anti-malarial drugs, either previously or still currently 
used to treat a P. falciparum infection, has been identi-
fied worldwide to various degrees [62, 63]. Thus, novel 
drugs need to overcome existing mechanisms of resist-
ance. A previous study has shown that SC83288 is 
active in vitro against various P. falciparum laboratory 
strains that are resistant to quinoline, quinoline-like 
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and antifolate anti-malarials [20]. This study extends 
these findings to include the artemisinin resistant par-
asite strain  NF54ART  that carry the kelch 13 mutation 
associated with reduced artemisinin responsiveness. 
SC83288 was found to be active against  NF54ART . Con-
versely, resistance to SC83288 did not affect the sus-
ceptibility of the parasite to other anti-malarial drugs, 
including artemisinins, chloroquine, mefloquine and 
the folate antagonists [20].
Conclusion
While this study does not provide molecular insights into 
the precise mode of action of SC83288, or into the pos-
sible mechanism of resistance, our study suggests that 
artemisinins and SC83288 target different molecular 
pathways, based on the absence of cross-reactivity in sev-
eral independent assays. The absence of cross-resistance 
and the ability to break established resistances against 
several anti-malarial drugs, together with a fast in  vitro 
parasite killing speed, are favourable features of SC83288 
and would support further development of this com-
pound, possibly as a treatment against severe malaria. 
Whether SC83288 can be an alternative to artesunate for 
the treatment of severe malaria, however, has to await 
clinical safety and efficacy trials in humans.
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